Dose-escalated radiotherapy plus long-term androgen deprivation therapy is safe and effective for patients with high-risk prostate cancer
A study, recently presented at the American Society of Clinical Oncology Genitourinary
Cancers Symposium in San Francisco found that high-risk prostate cancer patients benefit from dose-escalation radiotherapy in combination with long-term androgen deprivation therapy (ADT) with no increase in long-term toxicity.
The phase-3 trial of patients with high-risk prostate cancer and negative lymph node status was randomly assigned to receive either dose-escalated or conventional dose radiotherapy with ADT given to both groups.
The researchers found significantly improved biochemical or clinical progression-free survival in the dose- escalated group versus the conventional-dose group. Also, theresearchers found significant differences in prostate cancer-specific survival and overall survival. Late toxicities did not significantly differ between dose-escalated and conventional radiotherapy groups.
Oncology. February 4, 2024
